Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon and ursodeoxycholic acid combined therapy in chronic viral C hepatitis: controlled randomized trial in 203 patients.
Boucher E, Guyader D, Jacquelinet S, Andre P, Mendler MH, Turlin B, Canva V, Nousbaum JB, Bernard PH, Nouel O, Raabe JJ, Dao T, Gasser P, Verger P, Boutin J, Bergerault P, Joram F, Colmar P, Messner M, Brissot P, Deugnier Y. Boucher E, et al. Among authors: canva v. Dig Liver Dis. 2000 Jan-Feb;32(1):29-33. doi: 10.1016/s1590-8658(00)80041-9. Dig Liver Dis. 2000. PMID: 10975752 Clinical Trial.
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
de Lédinghen V, Trimoulet P, Winnock M, Foucher J, Bourlière M, Desmorat H, Canva V, Capron D, Lévy S, Mion F, Mannant PR, Chêne G, Fleury H, Couzigou P, Bernard PH; French Multicenter Study Group. de Lédinghen V, et al. Among authors: canva v. J Hepatol. 2002 May;36(5):672-80. doi: 10.1016/s0168-8278(02)00026-0. J Hepatol. 2002. PMID: 11983451 Clinical Trial.
Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.
Hézode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourlière M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Métivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group. Hézode C, et al. Among authors: canva v. J Hepatol. 2013 Sep;59(3):434-41. doi: 10.1016/j.jhep.2013.04.035. Epub 2013 May 10. J Hepatol. 2013. PMID: 23669289 Clinical Trial.
Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.
Hézode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP; CUPIC Study Group. Hézode C, et al. Among authors: canva v. Gastroenterology. 2014 Jul;147(1):132-142.e4. doi: 10.1053/j.gastro.2014.03.051. Epub 2014 Apr 3. Gastroenterology. 2014. PMID: 24704719 Free article.
Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.
About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L; ANRS CO20-CUPIC study group. About F, et al. PLoS One. 2015 Dec 15;10(12):e0145105. doi: 10.1371/journal.pone.0145105. eCollection 2015. PLoS One. 2015. PMID: 26670100 Free PMC article.
Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.
Dumortier J, Leroy V, Duvoux C, de Ledinghen V, Francoz C, Houssel-Debry P, Radenne S, d'Alteroche L, Fougerou-Leurent C, Canva V, di Martino V, Conti F, Kamar N, Moreno C, Lebray P, Tran A, Besch C, Diallo A, Rohel A, Rossignol E, Abergel A, Botta-Fridlund D, Coilly A, Samuel D, Duclos-Vallée JC, Pageaux GP. Dumortier J, et al. Among authors: canva v. Liver Transpl. 2016 Oct;22(10):1367-78. doi: 10.1002/lt.24505. Liver Transpl. 2016. PMID: 27348086 Free article. Clinical Trial.
80 results